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Abstract
Background: Elevated levels of air pollution are associated with increased risk of lung cancer. Particulate matter (PM) 
contains transition metals that may potentiate neoplastic development through the induction of oxidative stress and 
inflammation, a lung cancer risk factor. Vanadium pentoxide (V2O5) is a component of PM derived from fuel 
combustion as well as a source of occupational exposure in humans. In the current investigation we examined the 
influence of genetic background on susceptibility to V2O5-induced inflammation and evaluated whether V2O5 
functions as a tumor promoter using a 2-stage (initiation-promotion) model of pulmonary neoplasia in mice.
Results: A/J, BALB/cJ (BALB), and C57BL/6J (B6) mice were treated either with the initiator 3-methylcholanthrene (MCA; 
10 μg/g; i.p.) or corn oil followed by 5 weekly aspirations of V2O5 or PBS and pulmonary tumors were enumerated 20 
weeks following MCA treatment. Susceptibility to V2O5-induced pulmonary inflammation was assessed in 
bronchoalveolar lavage fluid (BALF), and chemokines, transcription factor activity, and MAPK signaling were quantified 
in lung homogenates. We found that treatment of animals with MCA followed by V2O5 promoted lung tumors in both 
A/J (10.3 ± 0.9 tumors/mouse) and BALB (2.2 ± 0.36) mice significantly above that observed with MCA/PBS or V2O5 
alone (P < 0.05). No tumors were observed in the B6 mice in any of the experimental groups. Mice sensitive to tumor 
promotion by V2O5 were also found to be more susceptible to V2O5-induced pulmonary inflammation and 
hyperpermeability (A/J>BALB>B6). Differential strain responses in inflammation were positively associated with 
elevated levels of the chemokines KC and MCP-1, higher NFκB and c-Fos binding activity, as well as sustained ERK1/2 
activation in lung tissue.
Conclusions: In this study we demonstrate that V2O5, an occupational and environmentally relevant metal oxide, 
functions as an in vivo lung tumor promoter among different inbred strains of mice. Further, we identified a positive 
relationship between tumor promotion and susceptibility to V2O5-induced pulmonary inflammation. These findings 
suggest that repeated exposures to V2O5 containing particles may augment lung carcinogenesis in susceptible 
individuals through oxidative stress mediated pathways.
Background
Lung cancer is the leading cause of cancer mortality in
the U.S. and worldwide [1]. Although cigarette smoke is
the main risk factor for lung cancer development,
approximately 10-15% of cases occur in never-smokers,
implicating other important environmental, occupa-
tional, and/or genetic factors [2-4]. Epidemiology studies
have suggested that long-term exposure to elevated levels
of particulate air pollution increases the risk of and mor-
tality due to lung cancer [5-8]. Particulate matter (PM) is
a complex mixture of particles that vary in physiochemi-
cal properties and are further classified according to the
aerodynamic size (PM2.5 = <2.5 μm; PM10 = ≤10 μm)
[9,10]. PM2.5 consists primarily of combustion products
derived from automobiles and the burning of coal, fuel
oil, and wood [9]. Most adverse health effects have been
attributed to this fraction, due to the ability to penetrate
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deep within the alveolar region of the lung [11]. Using
models developed by the World Bank, Cohen et. al. [12]
predicted that 5% of respiratory cancer mortality world-
wide is due to PM2.5.
The mechanism(s) contributing to increased lung can-
cer risk by PM have not been fully characterized,
although it has been suggested that pulmonary inflam-
mation mediated by particle-induced oxidative stress may
play an important role [13,14]. Generation of reactive
oxygen and nitrogen species (ROS/RNS) either directly or
through activation of phagocytes can cause oxidative
damage to DNA leading to initiation of cancer [14]. Addi-
tionally, ROS may potentiate tumor development by
stimulating production of pro-inflammatory mediators
that can promote expansion of initiated cells by influenc-
ing cell proliferation and apoptosis [14]. Oxidative stress
induced by PM is dependent on both the surface area of
the particle as well as its chemical composition [15].
Transition metals, and in particular vanadium com-
pounds, have been implicated as the active constituents
meditating oxidative lung injury in rodents exposed to
residual fly oil ash (ROFA) [16-18] as well as in some
studies using concentrated ambient air particles [19].
Vanadium pentoxide (V2O5) is the most common com-
mercial form of vanadium [20]. V2O5 is released into the
environment during oil and coal combustion and from
metallurgical works [20]. Occupational exposure can be
significant in the petrochemical, mining, and steel indus-
tries [20]. Additionally, military personnel and the gen-
eral public can be exposed to high levels of vanadium as a
result of incidental or intentional burning of fuel oils,
such as exposures that occurred during the K uwait oil
fires in 1991 [21]. Adverse respiratory effects have been
reported in humans, primates, and rodents exposed
acutely to V2O5. Coughing, wheezing, chest pain, bron-
chitis, and asthma-like symptoms as well as impaired
lung function occurred in humans exposed to high levels
of V2O5-containing dust [22-25]. In primates, inhalation
of V2O5 particles increased bronchoaveolar polymorpho-
nuclear neutrophils (PMNs) and impaired pulmonary
function [26], and in rodents, inhalation or intratracheal
administration induced PMN influx, synthesis of pro-
inflammatory mediators, as well as pulmonary fibrosis
[27-30].
Occupational and ambient exposure to vanadium has
been associated with an increase in biological markers for
oxidative DNA damage [31,32], however limited data are
available evaluating an association between V2O5 expo-
sure on lung cancer risk [33,34]. In vitro studies suggest
that vanadium functions as both an initiator and pro-
moter of morphological transformation in cultured cell
lines [35]. In a National Toxicology Program (NTP) study,
continuous inhalation of V2O5 (24 months inhalation; 1-4
mg/m3) resulted in a significant increase (~50%) in the
incidence of alveolar/bronchiolar neoplasms in both male
and female B6C3F1 mice [30]. Although this study dem-
onstrated the carcinogenic potential of V2O5, long-term
continuous exposure was required before tumors devel-
oped and no dose response was observed, which suggests
V2O5 may be promoting spontaneous tumors. In addi-
tion, different mouse strains were not assessed, which can
greatly influence pulmonary responses to environmental
pollutants [36] as well as susceptibility to carcinogenesis
[37,38].
This study was conducted to further evaluate the role of
V2O5 on pulmonary neoplasia among different inbred
strains of mice. Using a two-stage (initiation-promotion)
model, we hypothesized that inflammation induced by
sub-chronic V2O5 administration would promote tumori-
genesis in susceptible strains. Three strains of mice were
included in this study that display altered susceptibility to
chemical carcinogenesis: A/J mice are sensitive, BALB are
intermediate, whereas B6 mice are resistant to most short
term chemically-induced carcinogenesis protocols (eg.
not initiatable using MCA) [37-39]. These same three
strains also have similar differential susceptibility in
chronic pulmonary inflammation models [40-42]. Results
from this study demonstrate that V2O5 functions as an in
vivo lung tumor promoter in both A/J and BALB mice.
Further, we demonstrate a positive relationship between
tumor promotion and susceptibility to V2O5-induced
inflammation, involving the induction of the chemokines
KC and MCP-1, the transcription factors NFκB and c-
Fos, as well as sustained activation of ERK1/2 in pulmo-
nary tissue.
Methods
Animal husbandry
Male A/J, BALB/cJ (BALB), C57BL/6J (B6) mice were
purchased from Jackson Laboratories (Bar Harbor, ME)
at 5-6 weeks of age. Animals were housed in plastic, filter-
capped cages containing hardwood bedding and main-
tained in temperature (23 ± 2°C) and humidity (40-60%)
controlled rooms with a 12 hour light/dark cycle. Ani-
mals were given standard laboratory chow (Teklan foods,
Indianapolis, IN) and spring water ad libitum and were
assessed daily for health status. All mice were allowed one
week to acclimatize prior to treatment. Animal use was
conducted in AAALAC-accredited facilities and in accor-
dance with the regulatory guidelines of the Michigan
State University All University Committee on Animal Use
and Care.
Preparation and Administration of Vanadium Pentoxide
Pulmonary administration of vanadium pentoxide
(>99.9%, Sigma-Aldrich, St. Louis, MO) was performedRondini et al. Particle and Fibre Toxicology 2010, 7:9
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by oropharyngeal aspiration as previously described [43].
Briefly, V2O5 was suspended in sterile-filtered Dulbecco's
phosphate buffered saline (10 mM PBS, pH 7.4), soni-
cated for 20 minutes, then further diluted to a working
concentration of 2 mg/mL. Prior to aspirations mice were
anesthetized using 3% isoflurane in 1-2 L/min oxygen,
and V2O5 (4 mg/kg body weight) was administered fol-
lowing the methods of Foster et. al. [43]. This dose was
chosen based on preliminary dose response studies using
protocol 2 (Fig. 1B) described below (data not shown), as
well as previous acute lung injury models [28,29]. Control
animals received PBS alone (50 μL/mouse). V2O5 suspen-
sions were prepared fresh prior to use and administered
to animals within two hours of preparation.
Experimental Procedures
The experimental designs utilized in this study are
depicted in Figure 1. Protocol 1 (Fig. 1A) was conducted
to investigate whether sub-chronic exposure to V2O5
would promote pulmonary carcinogenesis using a two-
stage (initiation-promotion) model. Mice were injected
ip. (10 μg/g body weight) with the carcinogen MCA
(Sigma, St. Louis, MO) dissolved in corn oil or with corn
oil alone. Beginning one week later, mice were treated
with 5 weekly aspirations of either V2O5 (4 mg/kg) or PBS
as described above. To assess tumor promotion, animals
were sacrificed 20 weeks following MCA treatment; the
lungs were perfused with saline then inflated and fixed in
Tellyesniczky's fixative for 48 hrs. Tumors were enumer-
ated using an Olympus SZX7 stereomicroscope (Olym-
pus; Center Valley, PA) and sized with digital calipers
(Mitutoyo Corporation; Japan). Using this protocol, pul-
monary inflammation was additionally assessed in A/J
mice 21 days following the last aspiration as described
below.
To assess strain differences in inflammation, (protocol
2, Fig. 1B), mice were aspirated once per week for 4 weeks
with V2O5 (4 mg/kg) or PBS. At selected time intervals (6
hr, 1, 3, 6, and 21 days) following the last dose, bronchoa-
veolar lavage fluid (BALF) was collected to quantify dif-
ferences in cellular infiltrates and protein content, a
marker of hyperpermeability, as described previously
[44]. At each time point, the right lobes were snap frozen
in liquid nitrogen and stored at -80°C and the left lobe
was either snap frozen and stored or inflated with and
fixed overnight in 10% neutral buffered formalin for his-
tological examination.
Because several studies demonstrated that MCA can
induce p38 MAP Kinase, intracellular oxidants, as well as
transcription factor activity in HepG2 cells (a hepatoma
cell line) [45-47], an additional control experiment was
conducted to determine whether carcinogen (MCA)
administration influences pulmonary inflammation
between strains. Mice were injected ip. with MCA (10 μg/
g) dissolved in corn oil or oil alone, then aspirated with 4
weekly doses of PBS (Protocol 3, Fig. 1C) and sacrificed 6
hr or 1 day following the last aspiration. BALF was
assessed for protein content and cellular infiltrate as
described above.
Immunohistochemical Detection of PMNs
A neutrophil-specific marker (sc-59338) and ABC detec-
tion kit (sc-2019) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Left lungs were fixed in
10% NBF for 24 hrs, processed using standard histologi-
cal procedures, embedded, then cut into 5 μm sections.
Strain differences in pulmonary neutrophil infiltration
were evaluated using peroxidase biotin-streptavidin
immunohistochemistry, and bound enzyme was visual-
Figure 1 Experimental protocols. A.) V2O5 was evaluated as a tumor 
promoter using a two-stage carcinogenesis model. MCA suspended in 
corn oil (10 μg/g) was administered to initiate carcinogenesis followed 
by 5 weekly aspirations of V2O5 (4 mg/kg, promoter) or PBS. B.) A/J, 
BALB, and B6 mice were exposed to 4 weekly aspirations of V2O5 and 
sacrificed at select time points to assess pulmonary inflammation. C.) 
A/J, BALB, and B6 mice were administered MCA (10 μg/g) or oil and 
then exposed to 4 weekly aspirations of PBS and sacrificed at select 
time points to assess pulmonary inflammation.Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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ized using the chromagen 3-3'-diaminobenzidine (DAB).
Tissues were then lightly counterstained in Gill's hema-
toxylin.
Analysis of the chemokines KC, MIP-2, and MCP-1 by ELISA
ELISA kits for keratinocyte-derived chemokine (KC,
CXCL1), macrophage inflammatory protein-2 (MIP-2,
CXCL2), and monocyte chemoattractant protein 1
(MCP-1, CCL2) were purchased from R&D systems
(Minneapolis, MN). Protein was prepared by homogeniz-
ing lungs in ice-cold RIPA buffer (10 mM PBS, 0.5% SDS,
0.5% sodium deoxycholate) containing protease inhibi-
tors (Sigma, St. Louis, MO). Homogenates were centri-
fuged at 13,000 × g for 10 min at 4°C, and protein was
quantified using the DC protein assay (BioRad; Carlsbad,
CA). For chemokine analysis 25-50 μg of RIPA extracted
protein was used in accordance with manufacturer's
instructions. Absorbance was measured at 450 nm using
a VersaMax microplate reader (Molecular Devices,
Sunnyvale, CA). All data are presented as pg/mg protein.
Transcription factor assay for nuclear NFκB and c-Fos 
activity
Nuclear protein was prepared from the left lung of mice
using the TransAM nuclear extraction kit (Active Motif;
Carlsbad, CA) and quantified with the DC protein assay
(Biorad; Carlsbad, CA). Strain differences in binding of
NFκB (p65 subunit) and AP-1 (c-Fos) were then mea-
sured from 8 μg of nuclear protein using TransAM Tran-
scription Factor ELISA kits (Active Motif; Carlsbad, CA).
Absorbance was measured at 450 nm using a VersaMax
microplate reader (Molecular Devices, Sunnyvale, CA).
Immunoblotting analyses for MAPK activation
Primary antibodies specific for MAPKs were purchased
from Cell Signaling (Danvers, MA) and secondary anti-
bodies from Pierce (Thermo Fisher; Rockford, IL). Pro-
tein was prepared from right lungs as described above.
Samples (100 μg protein) were resolved on 12.5% SDS
polyacrylamide gels. Following transfer, PVDF mem-
branes were blocked for 1 hr at room temperature in 5%
nonfat dry milk, and then incubated with primary anti-
bodies to detect phosphorylated ERK1/2, JNK1/2, or p38
overnight at 4°C. After washing, blots were incubated in
secondary antibody linked to horseradish peroxidase for
1 hr at room temperature, and bands were detected using
chemiluminescence. Images were captured using BioRad
ChemiDoc illumination system (BioRad; Carlsbad, CA).
Following detection, membranes were stripped in Restore
stripping buffer (Thermo Fisher; Rockford, IL) then rep-
robed for total MAPK using procedures described above.
D e n s i t o m e t r y  o f  b a n d s  w e r e  q u a n t i f i e d  w i t h  B i o R a d
Quality One software and phosphorylated proteins were
normalized to the respective total MAPK prior to statisti-
cal analyses.
Statistical analyses
All statistical analyses were conducted using SAS statisti-
cal software (SAS institute version 8.2, Cary, North Caro-
lina). Time- and strain- dependent changes in BALF
protein, cellularity, chemokines, nuclear transcription
factor activity, protein densitometry, and tumor multi-
plicity/size were analyzed using an analysis of variance
(ANOVA). When statistical differences were detected (P
< 0.05), comparisons of means were analyzed using the
least significant difference (LSD) method. All data are
presented as mean ± SEM.
Results
Sub-chronic administration of V2O5 promotes pulmonary 
tumorigenesis in A/J and BALB mice
Strain differences in tumor multiplicity and size are pre-
sented in Table 1. We found that V2O5 functions primar-
Table 1: Lung tumor multiplicity and size (in parenthesis) among inbred mice following sub-chronic V2O5 exposure.a, b, c, d
Corn Oil (Control) MCA-treated
Strain PBS V2O5 PBS V2O5
A/J 0.0 ± 0.0 0.50 ± 0.50 3.3 ± 0.75#
(0.72 ± 0.036)#
10 ± 1.4*#
(0.72 ± 0.032)#
BALB 0.0 ± 0.0 0.0 ± 0.0 0.78 ± 0.28
(0.49 ± 0.039)
2.2 ± 0.36*
(0.63 ± 0.068)
a A/J, BALB, and B6 mice were treated with or without the initiator MCA (10 μg/g), followed by sub-chronic administration of V2O5 (4 mg/kg) 
or PBS.
b Number of mice per treatment group: A/J, Oil/PBS and Oil/V2O5 (n = 3), MCA/PBS (n = 4), MCA/V2O5 (n = 15); BALB, Oil/PBS and Oil/V2O5 (n 
= 3-5), MCA/PBS (n = 8), MCA/V2O5 (n = 13); B6, Oil/PBS and Oil/V2O5 (n = 3-8), MCA/PBS (n = 7), MCA/V2O5 (n = 12).
c No tumors were detected in B6 mice in any of the experimental groups examined (data not shown).
d A significant strain effect was detected for tumor size (mm) between A/J (0.72 ± 0.012) and BALB mice (0.59 ± 0.054) (P < 0.05).
* Significantly different from strain-matched MCA-treated/PBS controls (P < 0.05).
# Significantly different than treatment-matched BALB mice (A/J vs BALB, P < 0.05).Rondini et al. Particle and Fibre Toxicology 2010, 7:9
http://www.particleandfibretoxicology.com/content/7/1/9
Page 5 of 13
ily as a lung tumor promoter in both A/J and BALB mice
following a low dose of MCA given as an initiating agent
(Table 1; P < 0.05). For both strains, tumor multiplicity
was higher in V2O5- t r e a t e d  m i c e  c o m p a r e d  t o  M C A -
treated, PBS controls (P < 0.05). Additionally, a significant
difference in tumor multiplicity and size was observed
between BALB and A/J in the MCA group (Table 1). In
the absence of MCA, V2O5 exposure alone was not suffi-
cient to initiate tumorigenesis. No tumors were detected
in B6 mice in any of the experimental groups examined
(data not shown). In A/J and BALB mice, tumors were
further evaluated by histopathological analyses in a sub-
set of animals. A majority of the tumors were found to be
solid adenomas (80%) and the remaining papillary (20%),
consistent with previous studies using MCA [48].
A/J and BALB mice are more susceptible to V2O5-induced 
pulmonary hyperpermeability and inflammation than B6 
mice
To determine whether chronic inflammation was associ-
ated with tumor promotion, we evaluated strain differ-
ences in BALF cellularity and protein content up to 21
days following the final V2O5 dose (Fig. 2). In general, sus-
ceptibility to pulmonary inflammation and hyperperme-
ability proceeded in the order A/J>BALB>B6 mice (Fig.
2A-2E). BALF protein content increased significantly in
all strains at 6 hr following V2O5 exposure and returned
to baseline by 21 days (Fig. 2A, P < 0.05). The peak pro-
tein response was at 6 hr in BALB and B6 mice compared
to 1 day in the A/J strain. Furthermore, protein levels in
A/J mice remained significantly elevated above other
strains at 3 days.
The effects of V2O5 on BALF cellularity are depicted in
Fig. 2B-2E. As shown, the extent and duration of the
inflammatory response was significantly greater in A/J
mice at all time points examined (P < 0.05; Fig. 2B). The
most striking difference between strains was observed for
PMNs, which was highest at 1 day (Fig. 2D). A/J mice
exhibited a ~150-fold increase in the number of PMNs
infiltrating the lung representing 36% of the total cells
recovered compared to a 43-fold increase in BALB (34%)
and only a 16-fold increase (~7%) in B6 mice. By 21 days,
i n f l a m m a t i o n  c o m p l e t e l y  r e s o l v e d  i n  B 6  m i c e ,  b u t  t h e
total number of cells, primarily macrophages and some
lymphocytes, remained elevated in A/J and to a lesser
degree in BALB mice (P < 0.05).
The BALF results were further confirmed using histo-
logical staining with an anti-PMN marker in lung sec-
tions from the most (A/J) and least sensitive (B6) strains 1
day following the final V2O5 dose (Figure 3). Figures 3A-D
demonstrate higher PMN influx in the A/J strain com-
pared to both B6 mice and PBS controls. Positive staining
for PMNs was observed primarily around the bronchioles
and in close proximity to the alveolar epithelium,
although staining was also seen surrounding larger air-
ways. Increased cellularity of the bronchiolar and alveolar
epithelium, indicative of epithelial cell proliferation, was
also observed in A/J, but not B6 mice when compared to
PBS controls.
In a separate study, we assessed the inflammatory cell
profile in the most sensitive strain (A/J) 21 days following
the last V2O5 dose to determine any synergistic effect of
MCA on inflammation (Table 2). For all phenotypes
examined (BALF total protein, and total cells including
macrophages, lymphocytes, and PMNs), there were sig-
nificant increases in mice treated with V2O5 compared to
PBS controls. There were no significant differences
between animals treated with MCA or with oil in any of
the groups (Table 2), suggesting that V2O5 was primarily
driving the inflammatory response. The total cell num-
be r s  a n d  m a c r o p h a g e s  i n  t h i s  s t u d y  w e r e  h i g h e r  c o m -
pared to Protocol 2 at this time point (21 days), due to the
extra weekly dose of V2O5 used to maximize promotion.
To further confirm that strain differences in tumor pro-
motion were not due to differences in inflammatory
responses to MCA, an additional control experiment was
conducted (Fig. 1C, Protocol 3). MCA or oil was adminis-
tered to mice followed by 4 weekly doses of PBS and dif-
ferences in BALF protein content and cellularity were
measured at 6 hr and 1 day following the last aspiration
(Additional file 1, Table S1). BALB mice exhibited a sig-
nificant increase in protein levels compared to the other
strains, similar to that observed in Fig. 2. Both BALB and
A/J mice also had higher PMNs compared to B6 mice,
however no additional effects of MCA on inflammatory
cell types were observed within strains (Additional file 1,
Table S1). Thus, these results provide further evidence
that strain susceptibility to inflammation induced by
V2O5 and not to MCA is more strongly associated with
lung tumor promotion in our model.
Strain differences in V2O5-induced inflammatory 
chemokine (KC, MIP-2, MCP-1) expression
Differential strain responses were detected for the
chemokines KC and MCP-1 (Fig. 4A, C), with higher lev-
els observed in both A/J and BALB compared to B6 mice.
KC increased 3-fold and MCP-1 by 2.5-fold at 6 hr and
remained elevated in A/J mice at 1 day following the last
V2O5  dose (Fig. 4A, C; P  < 0.05). In BALB mice,
chemokine levels increased to a similar extent at 6 hr, but
levels declined sharply by 1 day. Comparably, only mod-
est increases (~1.5-fold) were seen in B6 mice. Strain
responses were more variable and less pronounced for
MIP-2 (Fig. 4B). MIP-2 increased significantly in all
strains at 6 hr, with overall changes of 1.5-fold in A/J, 1.1-
fold in BALB, and 1.2-fold in B6 mice.Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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Figure 2 A/J and BALB are susceptible to pulmonary inflammation and hyperpermeability in response to sub-chronic V2O5. A/J, BALB, and 
B6 mice were exposed to 4 weekly doses of V2O5 (4 mg/kg) by aspiration and sacrificed 0.25, 1, 3, 6, 21 days after the last exposure. A.) Bronchoalveolar 
lavage (BALF) protein (μg/mL) and B.) total cells, C.) macrophages, D.) PMNs, and (E) lymphocytes per mL of BALF. Data represent the mean ± SEM (n 
= 5-15 animals/group). *, significantly different than strain-matched PBS controls. †, significantly different than time-matched B6 mice. δ, significantly 
different than time-matched BALB mice (P < 0.05).Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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A/J mice have higher transcriptional activity of NFκB and 
AP-1 than B6 mice following V2O5
Nuclear transcription factor activity and MAPK signaling
(see below) were evaluated in the most sensitive (A/J) and
resistant (B6) strains (Fig. 5). Sub-chronic administration
of V2O5 resulted in higher nuclear NFκB binding activity
in A/J mice at both 6 hr and 1 day, with binding activity at
1 day significantly greater than all other groups (Fig. 5A;
P < 0.05). No corresponding changes were observed in B6
mice at the time points assessed (Fig. 5A). Nuclear activ-
ity for the AP-1 transcription factor, c-Fos increased sig-
nificantly in both strains, but more so at 6 hr in A/J
compared to B6 mice (Fig. 5B; P < 0.05).
V2O5 activates the MAPKs ERK1/2 and p38 in pulmonary 
tissue
Strain differences in MAPK signaling were assessed in
whole lung homogenates (Fig. 6). Compared to PBS con-
trols, a significant increase in phosphorylation of p38 and
ERK1/2 were observed in both A/J and B6 mice 6 hr fol-
Figure 3 Neutrophil influx into lungs of A/J mice in response to sub-chronic V2O5. Neutrophils were detected by immunohistochemical staining 
using an anti-mouse neutrophil antibody in formalin fixed lung sections. A.) PBS-treated A/J mouse; B.) PBS-treated B6 mouse, C.) V2O5-treated A/J 
mouse, 1 day; D.) V2O5-treated B6 mouse, 1 day. Original magnifications ×100, insets ×200. Arrows indicate areas with positive staining for neutrophils 
(red-brown in color), dashed boxes indicate areas magnified within the insets.
Table 2: Pulmonary inflammation and hyperpermeability in A/J mice treated with either corn oil or MCA (10 μg/g) and 
then aspirated with 5 weekly doses of V2O5 (4 mg/kg) or PBS.a
Treatment Protein (μg/mL) Total Cells (×103) Macrophages 
(×103)
Lymphocytes 
(×103)
PMNs
(×103)
Oil/PBS 129 ± 4.3 79.7 ± 8.8 73.7 ± 7.9 0.572 ± 0.12 0.422 ± 0.12
Oil/V2O5 166 ± 4.0* 156 ± 17* 147 ± 18* 4.14 ± 0.65* 0.737 ± 0.23*
MCA/PBS 132 ± 15 83.1 ± 11 76.3 ± 11 0.109 ± 0.07 0.271 ± 0.073
MCA/V2O5 198 ± 25* 161 ± 16* 149 ± 18* 6.01 ± 0.81* 1.47 ± 0.38*
a A/J mice were treated with corn oil (control) or MCA (10 μg/g) and then aspirated with 5 weekly doses of either PBS or V2O5 (4 mg/kg). 
Animals were sacrificed 21 days after the last aspiration. Protein (μg/mL) concentration and inflammation were measured in bronchoalveolar 
lavage fluid (BALF) and data are expressed as cells (×103) per mL of BALF. Data represent the mean ± SEM (n = 4-7 animals/group).
* Significantly different from PBS exposed animals (P < 0.05).Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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lowing V2O5  treatment. By one day, phospho-p38
returned to basal levels in both strains (Fig. 6B), whereas
phospho-ERK1/2 remained elevated in A/J mice (Fig. 6A;
P  < 0.05). No significant changes in JNK1/2 were
observed between or within strains at any of the time
points examined (Fig. 6C). Because MCA has been shown
to induce intracellular oxidant levels [46], we also mea-
sured the MAPKs ERK1/2 and p38 in B6 and A/J mice
from Protocol 3 (Additional file 2, Fig. 1S). There was a
slight but non-significant increase in phospho-p38 in
MCA-treated B6 mice 6 hr following the last PBS aspira-
tion, however no significant differences between strains
were observed for either MAPK examined (Additional
file 2, Fig. 1S).
Discussion
Chronic inflammation is a risk factor for several cancer
types [49]. Asthmatics and individuals with COPD are at
an elevated lifetime risk for developing lung cancer [50].
The importance of inflammation in augmenting pulmo-
nary carcinogenesis is further supported by a wide range
of pharmaceutical compounds that inhibit neoplastic
development [51] as well as evidence from transgenic
mouse models [52,53]. Because tumor promotion
involves changes in gene expression, most likely epige-
netic in nature, and is the only reversible stage of carcino-
genesis, studying promoters may identify additional
pathways to target for preventive strategies against
human lung cancer.
In the current investigation, we provide evidence that
V2O5 functions as an in vivo tumor promoter among dif-
ferentially susceptible inbred strains of mice. Using a two-
stage model of carcinogenesis, a significant increase in
tumor multiplicity was observed in both A/J (10.3 ± 0.9
tumors/mouse) and BALB (2.2 ± 0.36) mice exposed to
the carcinogen MCA followed by 5 weekly aspirations of
V2O5. The effect of V2O5 was limited to tumor promo-
tion, as no significant increase in tumor numbers were
observed in animals exposed to V2O5 alone. Susceptibility
to promotion paralleled relative strain sensitivity to
V2O5-induced inflammation: A/J mice were most sensi-
tive and BALB were intermediate. B6 mice were found to
be most resistant to V2O5-induced inflammation, how-
ever were used as a control since they are not initiated by
the low dose of MCA administered in this study [37].
Differences between the two susceptible strains of mice
(A/J and BALB) are not unusual based on past genome
mapping studies demonstrating distinct genes responsi-
ble for tumorigenesis in these specific strains [54,55].
While both strains are susceptible to lung tumor develop-
ment, differences in sensitivity between these two strains
has been linked to quantitative trait loci containing both
tumor suppressor genes as well as inflammatory media-
tors, such as myeloperoxidase (Mpo), colony stimulating
factor (Csf)3, CC chemokine receptor (Ccr10), and Ccl2
(Mcp-1) [54,55]. Although MCA was used as an initiating
agent in this study, additional control experiments fur-
Figure 4 The chemokines KC and MCP-1 are elevated in A/J and 
BALB mice following V2O5 treatment. A.) KC, keratinocyte chemoat-
tractant, B.) MIP-2, macrophage inflammatory protein-2, C.) MCP-1, 
monocyte chemoattractant protein-1 levels were determined in lung 
homogenates (25-50 μg protein) by ELISA. Values are presented as 
means ± SEM from two independent assays. *, significantly different 
than strain-matched PBS controls. †, significantly different than time-
matched B6 mice. δ, significantly different than time-matched BALB 
mice. **, significant treatment effect (6 hr V2O5 vs PBS control). ‡, signif-
icant strain effect (A/J vs B6, BALB vs B6). #, significant strain effect (A/J 
vs BALB) (P < 0.05).Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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ther demonstrated that carcinogen treatment alone did
not influence inflammatory indices between strains.
Because significant strain responses were observed only
in response to V2O5, our findings suggest that that
genetic (host) factors contributing to V2O5-induced pul-
monary inflammation are also strongly associated to lung
tumor promotion.
Vanadium is thought to mediate pulmonary inflamma-
tion through generation of multiple reactive oxygen spe-
cies (O2
-, H2O2, and ·OH) in target cells [56-58].
Production of ROS is associated with phosphorylation of
EGF-R and activation of MAPK signaling [57,59-63] as
well as the transcription factors NFκB [59,63], AP-1
[59,64], and STAT-1 [65]. Furthermore, vanadium is
known to be a phosphatase inhibitor [66] and likely pro-
longs phosphorylation and signaling along ROS-sensitive
pathways. These events, in turn can influence the synthe-
sis and release of pro-inflammatory cytokines and
chemokines mediating acute lung injury [29,65,67,68].
Pretreatment of human bronchial epithelial cells with
metal chelators and/or free radical scavengers reduces
vanadium-generated ROS, MAPK activation, as well as
release of chemokines, further supporting a role for oxi-
dative stress in vanadium-induced inflammation [62].
In our study, differential strain induction of chemok-
ines and upstream signaling molecules in response to
V2O5 correlated to the extent and duration of inflamma-
tory cells recovered in pulmonary tissue. MIP-2 and KC
are principle neutrophil chemoattractants in rodent
models, homologous to IL-8 in humans [69], whereas
MCP-1 induces monocyte and lymphocyte chemotaxis
and migration [70]. We observed moderate, although sig-
nificant induction of MIP-2 in all strains at 6 hr following
vanadium exposure, which likely involved initial PMN
influx. However, strain differences in the peak PMN
response were more closely associated with pulmonary
levels of KC. MCP-1 was highly induced in A/J and BALB
mice and expression coincided with the influx of both
monocytes and lymphocytes into pulmonary tissue. The
transcription factors NFκB and c-Fos as well as the
MAPK pERK1/2 were also found to be differentially regu-
lated in the sensitive (A/J) and resistant (B6) mice and
corresponded to both altered chemokine induction and
BALF cellularity.
The microenvironment is becoming increasingly recog-
nized as actively contributing to the tumorigenic process.
Evidence suggests that PMNs and macrophages appear to
be involved in tumor development through multiple
mechanisms, including more direct, such as induction of
DNA damage and regulation of cell cycle [71], as well as
indirect mechanisms, such as promotion of angiogenesis
by cytokines and chemokines and suppression of adaptive
immune responses [71,72]. Local production of cytokines
and chemokines may also stimulate expansion of initiated
cells by influencing cell proliferation and apoptotic path-
ways [14]. Several signaling molecules altered by V2O5 in
this study have been implicated in lung cancer develop-
ment. For example, IL-8 has been reported to serve as an
autocrine growth factor in lung cancer cell lines [73,74]
and both IL-8 and MCP-1 are elevated in bronchiolar epi-
Figure 5 NFκB and c-Fos are differentially regulated in A/J and B6 mice following V2O5 instillation. Nuclear binding activity for A.) NFκB and B.) 
c-Fos were determined by transcription factor ELISA TransAM kits in nuclear protein extracts (8 μg) prepared from the lungs of chronic V2O5 treated 
mice (n = 3-6/group). *, significantly different than strain-matched PBS controls (P < 0.05). †, significantly different than time-matched B6 mice (P < 
0.05).Rondini et al. Particle and Fibre Toxicology 2010, 7:9
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thelium from patients with COPD [75,76] and non-small
cell lung cancer (NSCLC) [77]. In mouse models, neutral-
ization of CXCR2, the principle receptor for KC and
MIP-2 reduces PMN infiltration [78] as well as tumor
growth and angiogenesis, suggesting a role in tumor pro-
gression [53,79,80]. Constitutive activation of pERK1/2
[81,82] and the transcription factors NFκB [83] and c-Fos
[84] have well known effects on cell cycle regulation.
Additional evidence for ERK1/2 in pulmonary tumori-
genesis was recently demonstrated in transgenic mice
overexpressing mutant B-raf and K-ras. Pharmacological
inhibition of pERK1/2 resulted in tumor regression by
inhibiting cell proliferation and restoring apoptosis [81].
Constitutive activation of ERK1/2 was also observed in
V2O5-induced mouse carcinomas from the NTP study
containing both K-ras mutations and loss of heterozygos-
ity [85], which supports findings in this model and sug-
gests involvement of ERK1/2 as one pathway driving
tumor promotion by V2O5.
Conclusions
Our study provides evidence that V2O5 functions as an in
vivo tumor promoter and suggests that susceptibility to
V2O5-induced inflammation and tumor promotion is
influenced by genetic background. Tumor promotion in
our model was associated with a robust inflammatory
response involving induction of multiple chemokines, the
transcription factors NFκB and c-Fos, as well as sustained
activation of ERK1/2 in susceptible mice. These findings
suggest that activation of oxidative stress-mediated sig-
naling events may be one mechanism contributing to
increased lung cancer risk by PM. A limitation in the cur-
rent study was that the dose of V2O5 utilized was signifi-
cantly higher than either occupational or ambient
exposure levels, and was not meant to be directly used for
risk assessment. It should be noted, however, that in the
NTP study, a significant increase in pulmonary tumors
was also reported after 2 years in B6C3F1 mice, a resis-
tant strain, at more relevant occupational levels of V2O5.
Although we found that V2O5 alone did not initiate tum-
origenesis, our findings highlight that repeated exposures
to inflammatory stimuli augments pulmonary carcino-
genesis in susceptible strains. Additional studies examin-
ing genetic differences in antioxidant enzyme levels and
adenoma susceptibility genes potentially contributing to
tumor promotion by V2O5 as well as to other PM constit-
uents warrant further investigation.
Additional material
Additional file 1 Table S1. Pulmonary inflammation and hyperperme-
ability in B6, BALB, and A/J mice treated with corn oil or MCA (10 μg/
g) and then aspirated with 4 weekly doses of PBS.
Additional file 2 Figure S1. The MAPKs ERK 1/2 and p38 are not signif-
icantly altered between B6 or A/J mice treated with the carcinogen 
MCA (10 μg/g) and then aspirated with 4 weekly doses of PBS. Homo-
genates were prepared from the right lungs of mice treated with either 
MCA or oil and then 4 weekly aspirations of PBS (n = 3-5/group). Phospho-
rylated and total levels of MAPK in lung homogenates were analyzed from 
75 μg protein by Western blotting. Representative images and mean band 
intensities are representative of 2-3 independent experiments. No signifi-
cant differences were observed for either of the MAPK tested (P > 0.05).
Figure 6 ERK1/2 is differentially activated in A/J compared to B6 
mice following sub-chronic V2O5 instillation. Homogenates were 
prepared from the right lungs of mice A.) 6 hr and B.) 1 day after the last 
V2O5 exposure (n = 3-5/group). Phosphorylated and total levels of 
MAPK in lung homogenates were analyzed from 100 μg protein by 
Western blotting. Representative images and mean band intensities 
are representative of 2-3 independent experiments. *, significantly dif-
ferent than strain-matched PBS controls (P < 0.05). **, significant main 
effect of time. †, significantly different than time-matched B6 mice (P < 
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